Lecturer in Small Animal Medicine Royal Veterinary College North Mymms, England, United Kingdom
Disclosure(s):
Rebecca F. Geddes, MA VetMB MVetMed PhD DACVIM(SAIM) FHEA MRCVS: No relevant disclosure to display
Presentation Description / Summary: Disruptions in calcium-phosphate homeostasis leading to chronic kidney disease-mineral and bone disorder (CKD-MBD) occur ubiquitously by the time feline patients reach end-stage CKD, but the onset of this sequelae is highly variable. Management of CKD-MBD with dietary phosphate restriction has been the mainstay of intervention for cats with CKD for over 20 years, but the degree of phosphate restriction best suited to each patient is not consistent. Fibroblast growth factor 23 (FGF23) has been found to be a useful biomarker of early CKD-MBD and can now be measured commercially, becoming a new tool for assessing the presence and severity of CKD-MBD in cats with International Renal Interest Society (IRIS) stage 1 and 2. Intriguingly, FGF23 concentrations vary widely across cats within the same IRIS stage and can be heavily impacted by other factors, for example, hypercalcemia. This lecture discusses how to best assess your feline patient with CKD for the presence of CKD-MBD and strategies to manage this condition.
Learning Objectives:
Upon completion, participant will be able to utilise FGF23 as a biomarker of CKD-MBD in early (IRIS stage 1 and 2) CKD.
Upon completion, participant will be able to identify factors that can affect FGF23 measurement.
Upon completion, participant will be able to develop a treatment plan for managing CKD-MBD in cats with CKD.
.jpg "Rebecca F. Geddes, MA VetMB MVetMed PhD DACVIM(SAIM) FHEA MRCVS (she/her/hers) photo")